1/1/24, 3:11 PM Revision 5

| ខ្លុ<br>Trk (pan)            |  |  |  |   |  |  |  |
|------------------------------|--|--|--|---|--|--|--|
| Trk (pan) (A7H6R) Rabbit mAb |  |  |  |   |  |  |  |
| Sto                          |  |  |  |   | Orders:  | 877-616-CELL (2355<br>orders@cellsignal.com  |  |
| T 6                          |  |  |  |   | Support:   | 877-678-TECH (8324   |  |
| 676-                         |  |  |  |   | Web:   | info@cellsignal.con<br>cellsignal.con  |  |
|                              |  |  |  | 3 Trasł   | Lane   Danvers   Mass  | sachusetts   01923   US  |  |
| or Research Use Only         |  |  |  |   |  |  |  |
| Applications:<br>WB, W-S, IP | Reactivity:<br>H M R   | Sensitivity:<br>Endogenous   | <b>MW (kDa):</b><br>120-140  | Source/Isotype:<br>Rabbit IgG   | UniProt ID:<br>#P04629, #Q16288,<br>#Q16620  | <b>Entrez-Gene ld:</b> 4914, 4916, 4915  |  |
| Product Usage<br>Information | А  | pplication   |  |   | Dilution   |  |  |
|                              | v  | /estern Blotting   |  |   | 1:1000   |  |  |
|                              | S  | imple Western™   |  |   | 1:10 - 1:50  |  |  |
|                              | Ir   | nmunoprecipitation   |  |   | 1:50   |  |  |
| Storage                      |  |  |  | 7.5), 150 mM NaCl, 10<br>o not aliquot the antibo   | 00 μg/ml BSA, 50% glyc<br>ody.   | erol and less than   |  |
| Specificity / Sensitivity    |  | Trk (pan) (A7H6R) Rabbit mAb detects endogenous levels of total Trk protein. This antibody detects TrkA,<br>TrkB and TrkC. However, the antibody may perferentially detect TrkA over TrkB and TrkB over TrkC.  |  |   |  |  |  |
| Source / Purification        |  | Monoclonal antibody is produced by immunizing animals with a synthetic peptide surrounding Tyr791 of human TrkA.   |  |   |  |  |  |
| -                            |  |  |  |   | rkB, and TrkC. While the   |  |  |
|                              | BL<br>ph<br>gru<br>pla<br>sy<br>kir<br>sit<br>(cl<br>in<br>su<br>su  | DNF or NT4, and TrkC<br>ysiological processes<br>owth and patterning (<br>asticity. TrkA regulates<br>stem (2). Phosphoryla<br>nase cascade (3,4). R<br>es reflects TrkA kinas<br>nimeras) cause ligand<br>many malignancies ir<br>ggest that expressior   | y conserved, the<br>C by NT3 (1). Ner<br>S, such as cell su<br>1). In the adult no<br>s proliferation and<br>ation at Tyr490 is<br>residues Tyr674//<br>re activity (3-6). F<br>I-independent re-<br>including breast, of<br>of TrkA in neurco   | ey are activated by diff<br>urotrophin signaling th<br>rvival, proliferation, ne<br>ervous system, the Trh<br>d is important for deve<br>s required for Shc asso<br>675 lie within the catal<br>Point mutations, deletion<br>ceptor dimerization ar<br>povarian, prostate, and<br>oblastomas may be a g   | erent neurotrophins: Trk<br>rough these receptors re<br>eural development, and a<br>c receptors regulate syna<br>elopment and maturation<br>ociation and activation of<br>ytic domain, and phosphons, and chromosomal r<br>ad activation of TrkA (7-1<br>thyroid carcinomas (8-1<br>good prognostic marker   | A by NGF, TrkB by<br>egulates a number of<br>axon and dendrite<br>aptic strength and<br>of the nervous<br>f the Ras-MAP<br>norylation at these<br>earrangements<br>.0). TrkA is activated<br>3). Research studies                    |  |
| Background Refe              | BE<br>ph<br>gro<br>pla<br>sy<br>kir<br>sit<br>(cl<br>in<br>su<br>gro<br>erences<br>1.<br>2.<br>3.<br>4.<br>5.<br>6.<br>7.<br>8.<br>9.<br>10.<br>11.<br>12.   | DNF or NT4, and TrKC<br>sysiological processes<br>owth and patterning (<br>asticity. TrkA regulated<br>stem (2). Phosphoryla<br>hase cascade (3,4). R<br>es reflects TrkA kinas<br>nimeras) cause ligand<br>many malignancies in<br>ggest that expression<br>owth arrest and differ<br>Huang, E.J. and Reic<br>Segal, R.A. and Gree<br>Stephens, R.M. et al.<br>Marsh, H.N. et al. (20<br>Obermeier, A. et al. (20<br>Obermeier, A. et al. (20<br>Obermeier, A. et al. (20<br>Revalo, J.C. et al. (20<br>Revalo, J.C. et al. (20<br>Revalo, J.C. et al. (20<br>Revalo, G.W. et al. (20<br>Revalo, G.W. et al. (20<br>Revalo, J.C. et al. (20<br>Revalo | y conserved, the<br>by NT3 (1). Net<br>s, such as cell su<br>1). In the adult no<br>s proliferation and<br>ation at Tyr490 is<br>residues Tyr674//<br>e activity (3-6). F<br>I-independent re-<br>including breast, of<br>of TrkA in neuror<br>entiation of cells<br>thardt, L.F. (2003)<br>chardt, L.F. (2004)<br>chardt, L.F. (2006)<br>chardt, L.F. (2006)<br>cha | ey are activated by diff<br>urotrophin signaling th<br>rvival, proliferation, ne<br>ervous system, the Tri-<br>d is important for deves<br>s required for Shc asso<br>675 lie within the catal<br>Point mutations, delete<br>ceptor dimerization ar<br>ovarian, prostate, and<br>oblastomas may be a g<br>originating from the ne<br>ablastomas may be a g<br>origination ar<br>ovarian, prostate, and<br>oblastomas may be a g<br>origination ar<br>ovarian, prostate, and<br>oblastomas may be a g<br>origination ar<br>ovarian, prostate, and<br>ablastomas may be a g<br>ovarian, prostate, and<br>ablastomas may be a g | erent neurotrophins: Trk<br>rough these receptors re<br>aural development, and a<br>creceptors regulate syna<br>elopment and maturation<br>optic domain, and phosph<br>ons, and chromosomal r<br>ad activation of TrkA (7-1<br>thyroid carcinomas (8-1<br>good prognostic marker<br>eural crest (10).<br>72, 609-42.<br>57 19, 463-89.                           | A by NGF, TrkB by<br>egulates a number of<br>axon and dendrite<br>aptic strength and<br>of the nervous<br>f the Ras-MAP<br>norylation at these<br>earrangements<br>.0). TrkA is activated<br>3). Research studies                    |  |
| Background Refe              | BE<br>ph<br>gru<br>pla<br>sy<br>kir<br>sit<br>(cl<br>in<br>su<br>gru<br>gru<br>2.<br>3.<br>4.<br>5.<br>6.<br>7.<br>8.<br>9.<br>10.<br>11.<br>12.<br>13.  | DNF or NT4, and TrKC<br>ysiological processes<br>owth and patterning (<br>asticity. TrkA regulates<br>stem (2). Phosphoryla<br>hase cascade (3,4). R<br>es reflects TrkA kinas<br>himeras) cause ligand<br>many malignancies in<br>ggest that expression<br>owth arrest and differ<br>Huang, E.J. and Reid<br>Stephens, R.M. et al.<br>(20<br>Obermeier, A. et al. (20<br>Obermeier, C. et al. (20<br>Greco, A. et al. (20<br>Ødegaard, E. et al. (20<br>Obermeier, E. et al. (20<br>Obermeier, C. et al. (20<br>Obermeier       | y conserved, the<br>by NT3 (1). Ner<br>s, such as cell su<br>1). In the adult no<br>s proliferation an<br>ation at Tyr490 is<br>residues Tyr674//<br>e activity (3-6). F<br>d-independent re-<br>ncluding breast, of<br>of TrkA in neuro-<br>entiation of cells<br>thardt, L.F. (2003<br>(1994) Neuron 1<br>(1994) Neuron 1<br>(1994) Neuron 1<br>(1994) Neuron 1<br>(1994) Neuron 1<br>(1994) Neuron 1<br>(1994) EMBO J 1<br>(1994) EMBO J 1<br>(1994) EMBO J 1<br>(001) Oncogene 2<br>(000) Mol Cell Endoor<br>(2007) Hum Patho  | ey are activated by diff<br>urotrophin signaling th<br>rvival, proliferation, ne<br>ervous system, the Trh<br>d is important for deves<br>a required for Shc asso<br>675 lie within the catal<br>Point mutations, deletic<br>ceptor dimerization ar<br>ovarian, prostate, and<br>oblastomas may be a g<br>originating from the ne<br>B) Annu Rev Biochem<br>90) Annu Rev Biochem<br>90) Annu Rev Neuroso<br>12, 691-705.<br>63, 999-1010.<br>2, 933-41.<br>3, 1585-90.<br>20, 1229-34.<br>Biol 20, 8655-66.<br>Dosomes Cancer 19, 11<br>ancer Lett 232, 90-8.<br>28, 1960-70.<br>crinol 321, 44-9.<br>Di 38, 140-6.   | erent neurotrophins: Trk<br>rough these receptors re<br>aural development, and a<br>creceptors regulate syna<br>elopment and maturation<br>optic domain, and phosph<br>ons, and chromosomal r<br>ad activation of TrkA (7-1<br>thyroid carcinomas (8-1<br>good prognostic marker<br>eural crest (10).<br>72, 609-42.<br>57 19, 463-89.                           | A by NGF, TrkB by<br>egulates a number of<br>axon and dendrite<br>aptic strength and<br>of the nervous<br>f the Ras-MAP<br>norylation at these<br>earrangements<br>0). TrkA is activated<br>3). Research studies<br>as TrkA signals  |  |
|                              | BE<br>ph<br>gro<br>pla<br>sy<br>kir<br>sit<br>(cl<br>in<br>su<br>gro<br>gro<br>erences<br>1.<br>2.<br>3.<br>4.<br>5.<br>6.<br>7.<br>8.<br>9.<br>10.<br>11.<br>12.<br>13.<br>10.<br>11.<br>12.<br>13. | DNF or NT4, and TrKC<br>ysiological processes<br>owth and patterning (<br>asticity. TrkA regulates<br>stem (2). Phosphoryla<br>hase cascade (3,4). R<br>es reflects TrkA kinas<br>himeras) cause ligand<br>many malignancies in<br>ggest that expression<br>owth arrest and differ<br>Huang, E.J. and Reid<br>Segal, R.A. and Gree<br>Stephens, R.M. et al.<br>(20<br>Obermeier, A. et al. (20<br>Obermeier, A. et al. (20<br>Greco, A. et al. (20<br>Greco, A. et al. (20<br>Ødegaard, E. et al. (20<br>ecies reactivity is dete  | y conserved, the<br>by NT3 (1). Ner<br>s, such as cell su<br>1). In the adult no<br>s proliferation an<br>ation at Tyr490 is<br>residues Tyr674//<br>e activity (3-6). F<br>d-independent re-<br>ncluding breast, of<br>of TrkA in neuro-<br>entiation of cells<br>thardt, L.F. (2003<br>enberg, M.E. (1994) <i>Neuron</i> 1<br>003) <i>J Cell Biol</i> 1<br>1994) <i>Neuron</i> 1<br>003) <i>J Cell Biol</i> 1<br>1994) <i>EMBO</i> J 1<br>001) <i>Oncogene</i> 2<br>2000) <i>Mol Cell Biol</i><br>2000) <i>Mol Cell Biol</i><br>2007) <i>Hum Patho</i><br>ermined by testin  | ey are activated by diff<br>urotrophin signaling th<br>rvival, proliferation, ne<br>ervous system, the Trh<br>d is important for deves<br>a required for Shc asso<br>675 lie within the catal<br>Point mutations, deletic<br>ceptor dimerization ar<br>ovarian, prostate, and<br>oblastomas may be a g<br>originating from the ne<br>8) Annu Rev Biochem<br>96) Annu Rev Biochem<br>96) Annu Rev Neuroso<br>12, 691-705.<br>63, 999-1010.<br>2, 933-41.<br>3, 1585-90.<br>20, 1229-34.<br>Biol 20, 8655-66.<br>Dosomes Cancer 19, 11<br>ancer Lett 232, 90-8.<br>28, 1960-70.<br>crinol 321, 44-9.<br>ol 38, 140-6.<br>g in at least one appro-<br>e membrane with dilute   | erent neurotrophins: Trk<br>rough these receptors re<br>aural development, and a<br>c receptors regulate syna<br>elopment and maturation<br>ociation and activation of<br>ytic domain, and phosphons, and chromosomal r<br>ad activation of TrkA (7-1<br>thyroid carcinomas (8-1<br>good prognostic marker<br>eural crest (10).<br>72, 609-42.<br>ci 19, 463-89. | A by NGF, TrkB by<br>egulates a number of<br>axon and dendrite<br>aptic strength and<br>of the nervous<br>f the Ras-MAP<br>norylation at these<br>earrangements<br>.0). TrkA is activated<br>3). Research studies<br>as TrkA signals |  |

| 1/1/24, 3:11 PM<br>Cross-Reactivity Key | <ul> <li>Trk (pan) (A7H6R) Rabbit mAb (#92991) Datasheet Without Images Cell Signaling Technology</li> <li>H: human M: mouse R: rat Hm: hamster Mk: monkey Vir: virus Mi: mink C: chicken Dm: D. melanogaster</li> <li>X: Xenopus Z: zebrafish B: bovine Dg: dog Pg: pig Sc: S. cerevisiae Ce: C. elegans Hr: horse</li> <li>GP: Guinea Pig Rab: rabbit All: all species expected</li> </ul>   |
|---|--|
| Trademarks and<br>Patents               | Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.<br>XP is a registered trademark of Cell Signaling Technology, Inc.<br>All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more<br>information.   |
| Limited Uses                            | Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.  |
|   | Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products. |